Study summary
Intravenous iron modestly reduced heart failure hospital stays or death
141cardiovascular deaths or first heart failure hospitalizations with iron, vs 166 with placebo
What was tested
Ferric carboxymaltose, intravenous iron, against placebo in heart failure (ejection fraction 45% or less) with iron deficiency.
What they found
- Cardiovascular death or first hospitalization occurred in 141 vs 166 people, a borderline result.
- Serious side effects were similar.
What it means
Iron testing and treatment remain reasonable; the size of benefit is modest.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.